Status:
COMPLETED
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborating Sponsors:
Texas Children's Cancer Center
National Cancer Institute (NCI)
Conditions:
Neuroblastoma
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE1
Brief Summary
Neuroblastoma affects approximately 500 children a year in the United States. When the tumor occurs in infants, it is frequently localized and responds well to therapy. Even disseminated disease can b...
Detailed Description
Secondary objectives for this protocol included the following: * To determine whether major histocompatibility complex (MHC) restricted or unrestricted antitumor immune responses are induced by injec...
Eligibility Criteria
Inclusion
- Diagnosis of recurrent advanced stage neuroblastoma.
- Must have a life expectancy of at least 8 weeks.
- Must have recovered from the toxic effects of all prior chemotherapy before entering this study, and have an absolute neutrophil count of \>500/mm3.
- Not be currently receiving any investigational agents or have not received any tumor vaccines within the previous six months.
- Bilirubin \<1.5 mg/dl.
- Creatinine \<1.5 mg/dl.
- ECOG performance status of 0-2 as below:
- Does not have rapidly progressive disease.
- Not pregnant or lactating.
Exclusion
Key Trial Info
Start Date :
August 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00186862
Start Date
August 1 1998
End Date
October 1 2007
Last Update
June 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105